Data:
{
"symbol": "GMAB",
"price": 34.8048,
"marketCap": 21367915864,
"beta": 0.699,
"lastDividend": 0,
"range": "23.62-35.66",
"change": -0.5152,
"changePercentage": -1.45866,
"volume": 567733.35751,
"averageVolume": 2166156,
"companyName": "Genmab A/S",
"currency": "USD",
"cik": "0001434265",
"isin": "US3723032062",
"cusip": "372303206",
"exchangeFullName": "NASDAQ Global Select",
"exchange": "NASDAQ",
"industry": "Biotechnology",
"website": "https://www.genmab.com",
"description": "Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.",
"ceo": "Jan van de Winkel",
"sector": "Healthcare",
"country": "DK",
"fullTimeEmployees": "3119",
"phone": "45 70 20 27 28",
"address": "Carl Jacobsens Vej 30",
"city": "Copenhagen",
"state": "CD",
"zip": "2500",
"image": "https://images.financialmodelingprep.com/symbol/GMAB.png",
"ipoDate": "2009-06-01",
"defaultImage": false,
"isEtf": false,
"isActivelyTrading": true,
"isAdr": true,
"isFund": false
}
Data:
{
"symbol": "GMAB",
"name": "Genmab A/S",
"price": 35.63,
"changePercentage": 0.16868,
"change": 0.06000107,
"volume": 149422,
"dayLow": 35.5,
"dayHigh": 35.78,
"yearHigh": 35.77,
"yearLow": 23.62,
"marketCap": 21874536416,
"priceAvg50": 32.2987,
"priceAvg200": 29.57698,
"exchange": "NASDAQ",
"open": 35.78,
"previousClose": 35.57,
"timestamp": 1790775449,
"quote_spread": {},
"chart_vwap_daily": [
{
"t": "2026-08-19",
"v": 33.8418,
"c": 34.11
},
{
"t": "2026-08-20",
"v": 33.4979,
"c": 33.41
},
{
"t": "2026-08-21",
"v": 33.5545,
"c": 33.45
},
{
"t": "2026-08-24",
"v": 33.1017,
"c": 33.02
},
{
"t": "2026-08-25",
"v": 34.2134,
"c": 34.36
},
{
"t": "2026-08-26",
"v": 33.6578,
"c": 33.75
},
{
"t": "2026-08-27",
"v": 33.9656,
"c": 34.1
},
{
"t": "2026-08-28",
"v": 33.387,
"c": 33.23
},
{
"t": "2026-08-31",
"v": 33.0358,
"c": 33.16
},
{
"t": "2026-09-01",
"v": 33.3294,
"c": 33.29
},
{
"t": "2026-09-02",
"v": 34.0621,
"c": 34.215
},
{
"t": "2026-09-03",
"v": 34.299,
"c": 34.41
},
{
"t": "2026-09-04",
"v": 33.7123,
"c": 33.6
},
{
"t": "2026-09-08",
"v": 33.6428,
"c": 33.53
},
{
"t": "2026-09-09",
"v": 33.2615,
"c": 33.04
},
{
"t": "2026-09-10",
"v": 32.3595,
"c": 32.23
},
{
"t": "2026-09-11",
"v": 32.5019,
"c": 32.47
},
{
"t": "2026-09-14",
"v": 32.7026,
"c": 32.65
},
{
"t": "2026-09-15",
"v": 33.6466,
"c": 34.15
},
{
"t": "2026-09-16",
"v": 34.3526,
"c": 34.4
},
{
"t": "2026-09-17",
"v": 34.5353,
"c": 34.535
},
{
"t": "2026-09-18",
"v": 34.8835,
"c": 34.74
},
{
"t": "2026-09-21",
"v": 34.7035,
"c": 34.69
},
{
"t": "2026-09-22",
"v": 34.9997,
"c": 35.22
},
{
"t": "2026-09-23",
"v": 35.0103,
"c": 34.75
},
{
"t": "2026-09-24",
"v": 34.7248,
"c": 34.83
},
{
"t": "2026-09-25",
"v": 35.0711,
"c": 35.32
},
{
"t": "2026-09-28",
"v": 35.2107,
"c": 35.36
},
{
"t": "2026-09-29",
"v": 35.3273,
"c": 35.57
},
{
"t": "2026-09-30",
"v": 35.6193,
"c": 35.56
}
],
"vwap_summary": {
"days": 30,
"days_above": 14,
"days_below": 16,
"pct_days_above": 47,
"position": "below",
"gap_pct": -0.17,
"streak_days": 1
}
}
Data:
{
"volume": 149422,
"avgVolume": 2166156,
"short_ratio": [
{
"symbol": "GMAB",
"file_date": "2026-09-29",
"date": "20260929",
"short_volume": 1295230,
"short_exempt_volume": 35207,
"total_volume": 1796455,
"short_volume_ratio": 0.721,
"signal": "Bearish"
}
],
"volume_profile": {
"poc": 34.81,
"vah": 35.63,
"val": 34.1,
"profile": [
{
"price": 32.27,
"volume": 234842
},
{
"price": 32.32,
"volume": 257651
},
{
"price": 32.38,
"volume": 140486
},
{
"price": 32.44,
"volume": 406778
},
{
"price": 32.49,
"volume": 402899
},
{
"price": 32.55,
"volume": 398066
},
{
"price": 32.61,
"volume": 208760
},
{
"price": 32.66,
"volume": 496378
},
{
"price": 32.72,
"volume": 467212
},
{
"price": 32.78,
"volume": 268565
},
{
"price": 32.83,
"volume": 94795
},
{
"price": 32.89,
"volume": 44378
},
{
"price": 32.95,
"volume": 15430
},
{
"price": 33.0,
"volume": 276217
},
{
"price": 33.06,
"volume": 224653
},
{
"price": 33.11,
"volume": 92771
},
{
"price": 33.17,
"volume": 212998
},
{
"price": 33.23,
"volume": 492304
},
{
"price": 33.28,
"volume": 398653
},
{
"price": 33.34,
"volume": 246755
},
{
"price": 33.4,
"volume": 360705
},
{
"price": 33.45,
"volume": 151655
},
{
"price": 33.51,
"volume": 536963
},
{
"price": 33.57,
"volume": 662123
},
{
"price": 33.62,
"volume": 544425
},
{
"price": 33.68,
"volume": 406907
},
{
"price": 33.74,
"volume": 423897
},
{
"price": 33.79,
"volume": 377824
},
{
"price": 33.85,
"volume": 347983
},
{
"price": 33.91,
"volume": 380688
},
{
"price": 33.96,
"volume": 308479
},
{
"price": 34.02,
"volume": 604101
},
{
"price": 34.07,
"volume": 542599
},
{
"price": 34.13,
"volume": 1107667
},
{
"price": 34.19,
"volume": 261678
},
{
"price": 34.24,
"volume": 753267
},
{
"price": 34.3,
"volume": 768942
},
{
"price": 34.36,
"volume": 726503
},
{
"price": 34.41,
"volume": 951593
},
{
"price": 34.47,
"volume": 1001731
},
{
"price": 34.53,
"volume": 1450084
},
{
"price": 34.58,
"volume": 743723
},
{
"price": 34.64,
"volume": 945732
},
{
"price": 34.7,
"volume": 1492623
},
{
"price": 34.75,
"volume": 1903378
},
{
"price": 34.81,
"volume": 2038092
},
{
"price": 34.86,
"volume": 1641429
},
{
"price": 34.92,
"volume": 1304728
},
{
"price": 34.98,
"volume": 1711746
},
{
"price": 35.03,
"volume": 723886
},
{
"price": 35.09,
"volume": 687462
},
{
"price": 35.15,
"volume": 439281
},
{
"price": 35.2,
"volume": 894545
},
{
"price": 35.26,
"volume": 1286642
},
{
"price": 35.32,
"volume": 1073365
},
{
"price": 35.37,
"volume": 1018314
},
{
"price": 35.43,
"volume": 807331
},
{
"price": 35.49,
"volume": 682302
},
{
"price": 35.54,
"volume": 1051703
},
{
"price": 35.6,
"volume": 526512
}
],
"sessions": 20
}
}
Data:
{
"symbol": "GMAB",
"marketCap": 21832161905.5722,
"enterpriseValueTTM": 25639481840.453518,
"evToSalesTTM": 2.654812714817329,
"evToOperatingCashFlowTTM": 28.667417365871476,
"evToFreeCashFlowTTM": 29.43055836428566,
"evToEBITDATTM": 18.370690846651218,
"netDebtToEBITDATTM": 2.7051428214271813,
"currentRatioTTM": 2.4570175438596493,
"incomeQualityTTM": 1.0380457878431262,
"grahamNumberTTM": 167.57537455462932,
"grahamNetNetTTM": -6.66,
"taxBurdenTTM": 0.8696316718514625,
"interestBurdenTTM": 0.6684339247274469,
"workingCapitalTTM": 1661000000,
"investedCapitalTTM": 11142000000,
"returnOnAssetsTTM": 0.06298117794646424,
"operatingReturnOnAssetsTTM": 0.10707630638490478,
"returnOnTangibleAssetsTTM": 0.23972306630170317,
"returnOnEquityTTM": 0.1357890722576668,
"returnOnInvestedCapitalTTM": 0.099111586199859,
"returnOnCapitalEmployedTTM": 0.11709563797802197,
"earningsYieldTTM": 0.036137011613440136,
"freeCashFlowYieldTTM": 0.03984569392452022,
"capexToOperatingCashFlowTTM": 0.02593022493722937,
"capexToDepreciationTTM": 0.24635790425531914,
"capexToRevenueTTM": 0.002401328657648237,
"salesGeneralAndAdministrativeToRevenueTTM": 0.07553188820046289,
"researchAndDevelopementToRevenueTTM": 0.1851527562830493,
"stockBasedCompensationToRevenueTTM": 0.016176398893148362,
"intangiblesToTotalAssetsTTM": 0.7372752696763883,
"averageReceivablesTTM": 1154990178.5,
"averagePayablesTTM": 430074242,
"averageInventoryTTM": 19489615.5,
"daysOfSalesOutstandingTTM": 48.446240787685355,
"daysOfPayablesOutstandingTTM": 0,
"daysOfInventoryOutstandingTTM": 22.76923426472544,
"operatingCycleTTM": 71.2154750524108,
"cashConversionCycleTTM": 71.2154750524108,
"freeCashFlowToEquityTTM": 731790703,
"freeCashFlowToFirmTTM": 1103701416.43974,
"tangibleAssetValueTTM": -3270000000,
"netCurrentAssetValueTTM": -3757000000,
"grossProfitMarginTTM": 0.39918383607394,
"ebitMarginTTM": 0.14060638758676325,
"ebitdaMarginTTM": 0.1445134936393137,
"operatingProfitMarginTTM": 0.13811771083397117,
"pretaxProfitMarginTTM": 0.09398607949636872,
"continuousOperationsProfitMarginTTM": 0.08173327144319159,
"netProfitMarginTTM": 0.08173327144319159,
"bottomLineProfitMarginTTM": 0.08173327144319159,
"receivablesTurnoverTTM": 7.53412430078125,
"payablesTurnoverTTM": 0,
"inventoryTurnoverTTM": 16.030402944444443,
"fixedAssetTurnoverTTM": 37.96724057086614,
"assetTurnoverTTM": 0.7705696448262086,
"quickRatioTTM": 2.4412280701754385,
"solvencyRatioTTM": 0.13452416010978957,
"cashRatioTTM": 1.318421052631579,
"priceToEarningsRatioTTM": 27.829506249999998,
"priceToEarningsGrowthRatioTTM": -0.3250734840364412,
"forwardPriceToEarningsGrowthRatioTTM": -0.8992425338472525,
"priceToEarningsDilutedRatioTTM": 28.04863622047244,
"priceToEarningsDilutedGrowthRatioTTM": -0.32766126354229563,
"priceToBookRatioTTM": 3.6677822762205405,
"priceToSalesRatioTTM": 2.267752960497696,
"priceToFreeCashFlowRatioTTM": 25.139715312950546,
"priceToOperatingCashFlowRatioTTM": 24.464879289443818,
"debtToAssetsRatioTTM": 0.42133439872153416,
"debtToEquityRatioTTM": 0.8851771025684069,
"debtToCapitalRatioTTM": 0.46954585930543186,
"longTermDebtToCapitalRatioTTM": 0.44832376365993704,
"financialLeverageRatioTTM": 2.1008897095853616,
"workingCapitalTurnoverRatioTTM": 6.314158843453374,
"operatingCashFlowRatioTTM": 0.7833993719298246,
"operatingCashFlowSalesRatioTTM": 0.09260732074099846,
"freeCashFlowOperatingCashFlowRatioTTM": 0.9740697750627706,
"debtServiceCoverageRatioTTM": 2.271695146781904,
"interestCoverageRatioTTM": 4.979933270773359,
"shortTermOperatingCashFlowCoverageRatioTTM": 3.0376710340136053,
"operatingCashFlowCoverageRatioTTM": 0.1693675865731083,
"capitalExpenditureCoverageRatioTTM": 38.56503375581012,
"dividendPaidAndCapexCoverageRatioTTM": 38.56503375581012,
"dividendPayoutRatioTTM": 0,
"dividendYieldTTM": 0,
"revenuePerShareTTM": 15.72,
"netIncomePerShareTTM": 1.29,
"interestDebtPerShareTTM": 9.03,
"cashPerShareTTM": 2.45,
"bookValuePerShareTTM": 9.71,
"tangibleBookValuePerShareTTM": -5.33,
"shareholdersEquityPerShareTTM": 9.71,
"operatingCashFlowPerShareTTM": 1.46,
"capexPerShareTTM": 0.0378,
"freeCashFlowPerShareTTM": 1.42,
"netIncomePerEBTTTM": 0.8696316718514625,
"ebtPerEbitTTM": 0.6804781148548552,
"priceToFairValueTTM": 3.6677822762205405,
"debtToMarketCapTTM": 0.2348020880175327,
"effectiveTaxRateTTM": 0.1303683281485375,
"enterpriseValueMultipleTTM": 18.39746956122425,
"dividendPerShareTTM": 0,
"revenue_history": [
{
"date": "2025",
"revenue": 3722933872
}
],
"dcf": {
"symbol": "GMAB",
"date": "2026-09-29",
"dcf": 4.941188458904152,
"Stock Price": 35.45
},
"statements": {
"income": [
{
"date": "2025-12-31",
"symbol": "GMAB",
"reportedCurrency": "USD",
"cik": "0001434265",
"filingDate": "2026-02-17",
"acceptedDate": "2026-02-17 11:17:06",
"fiscalYear": "2025",
"period": "FY",
"revenue": 3722933872,
"costOfRevenue": 309243699,
"grossProfit": 3413690171,
"researchAndDevelopmentExpenses": 1560229544,
"generalAndAdministrativeExpenses": 0,
"sellingAndMarketingExpenses": 0,
"sellingGeneralAndAdministrativeExpenses": 602474782,
"otherExpenses": 0,
"operatingExpenses": 2162704326,
"costAndExpenses": 2471948027,
"netInterestIncome": 77060727,
"interestIncome": 138108836,
"interestExpense": 61048108,
"depreciationAndAmortization": 71055995,
"ebitda": 1337053667,
"ebit": 1265997672,
"nonOperatingIncomeExcludingInterest": -15011829,
"operatingIncome": 1250985843,
"totalOtherIncomeExpensesNet": -46036278,
"incomeBeforeTax": 1204949564,
"incomeTaxExpense": 241190069,
"netIncomeFromContinuingOperations": 963759494,
"netIncomeFromDiscontinuedOperations": 0,
"otherAdjustmentsToNetIncome": 0,
"netIncome": 963759493,
"netIncomeDeductions": 0,
"bottomLineNetIncome": 963759493,
"eps": 1.55,
"epsDiluted": 1.54,
"weightedAverageShsOut": 621510850,
"weightedAverageShsOutDil": 626916300
}
],
"balance_sheet": [
{
"date": "2025-12-31",
"symbol": "GMAB",
"reportedCurrency": "USD",
"cik": "0001434265",
"filingDate": "2026-02-17",
"acceptedDate": "2026-02-17 11:17:06",
"fiscalYear": "2025",
"period": "FY",
"cashAndCashEquivalents": 1711087203,
"shortTermInvestments": 0,
"cashAndShortTermInvestments": 1711087203,
"netReceivables": 1149371695,
"accountsReceivables": 1109462956,
"otherReceivables": 39908739,
"inventory": 17958932,
"prepaids": 0,
"otherCurrentAssets": 3,
"totalCurrentAssets": 2878417833,
"propertyPlantEquipmentNet": 279361175,
"goodwill": 354190061,
"intangibleAssets": 9102185750,
"goodwillAndIntangibleAssets": 9456375812,
"longTermInvestments": 58865389,
"taxAssets": 170609860,
"otherNonCurrentAssets": 4,
"totalNonCurrentAssets": 9965212240,
"otherAssets": 0,
"totalAssets": 12843630073,
"totalPayables": 1109462955,
"accountPayables": 1066561061,
"otherPayables": 42901894,
"accruedExpenses": 0,
"shortTermDebt": 273000000,
"capitalLeaseObligationsCurrent": 18000000,
"taxPayables": 0,
"deferredRevenue": 23945243,
"otherCurrentLiabilities": -663919,
"totalCurrentLiabilities": 1423744279,
"longTermDebt": 5001000000,
"capitalLeaseObligationsNonCurrent": 133694276,
"deferredRevenueNonCurrent": 94783255,
"deferredTaxLiabilitiesNonCurrent": 363169528,
"otherNonCurrentLiabilities": 5000000,
"totalNonCurrentLiabilities": 5586225804,
"otherLiabilities": 0,
"capitalLeaseObligations": 151694276,
"totalLiabilities": 7009970084,
"treasuryStock": 0,
"preferredStock": 0,
"commonStock": 9977184,
"retainedEarnings": 4088650356,
"additionalPaidInCapital": 1915619493,
"accumulatedOtherComprehensiveIncomeLoss": -180587045,
"otherTotalStockholdersEquity": 0,
"totalStockholdersEquity": 5833659988,
"totalEquity": 5833659988,
"minorityInterest": 0,
"totalLiabilitiesAndTotalEquity": 12843630073,
"totalInvestments": 58865389,
"totalDebt": 5426000000,
"netDebt": 3714912797
}
],
"cash_flow": [
{
"date": "2025-12-31",
"symbol": "GMAB",
"reportedCurrency": "USD",
"cik": "0001434265",
"filingDate": "2026-02-17",
"acceptedDate": "2026-02-17 11:17:06",
"fiscalYear": "2025",
"period": "FY",
"netIncome": 963759493,
"depreciationAndAmortization": 71055995,
"deferredIncomeTax": 0,
"stockBasedCompensation": 0,
"changeInWorkingCapital": 225177451,
"accountsReceivables": -166130919,
"inventory": -9007097,
"accountsPayables": 400315469,
"otherWorkingCapital": 0,
"otherNonCashItems": -73057572,
"netCashProvidedByOperatingActivities": 1186935368,
"investmentsInPropertyPlantAndEquipment": -55043376,
"acquisitionsNet": -7220690293,
"purchasesOfInvestments": -995784731,
"salesMaturitiesOfInvestments": 2624067906,
"otherInvestingActivities": 0,
"netCashProvidedByInvestingActivities": -5647450495,
"netDebtIssuance": 5231122405,
"longTermNetDebtIssuance": -2039700,
"shortTermNetDebtIssuance": 5231122405,
"netStockIssuance": -407320989,
"netCommonStockIssuance": -407320989,
"commonStockIssuance": 23018139,
"commonStockRepurchased": -430339130,
"netPreferredStockIssuance": 0,
"netDividendsPaid": 0,
"commonDividendsPaid": 0,
"preferredDividendsPaid": 0,
"otherFinancingActivities": -31024449,
"netCashProvidedByFinancingActivities": 4792776966,
"effectOfForexChangesOnCash": 13063437,
"netChangeInCash": 345325277,
"cashAtEndOfPeriod": 1711087203,
"cashAtBeginningOfPeriod": 1365761926,
"operatingCashFlow": 1186935368,
"capitalExpenditure": -37029182,
"freeCashFlow": 1149906186,
"incomeTaxesPaid": 0,
"interestPaid": 0
}
]
}
}
Data:
{
"price": 35.65,
"rsi": 67.83176767783948,
"sma20": 34.268000000000036,
"sma50": 32.44440000000007,
"sma200": 29.593799999999973,
"adx": 29.881906085190646,
"atr": 0.76,
"atr_pct": 2.13,
"atr_expansion_pct": -2.2,
"di_plus": 38.4,
"di_minus": 5.7,
"high_52w": 35.65,
"low_52w": 23.85,
"structure": {
"ema8": 35.15349349402166,
"ema21": 34.332608535894956,
"ema50": 32.67101965888662,
"ema200": 29.589057546204433,
"ema10": 35.013546844527475,
"ema20": 34.39289333114423,
"ema10_slope_pct": 2.04,
"ema20_slope_pct": 1.91,
"trend_dir": "up",
"checks": {
"price_above_all": true,
"ema_stacked": true,
"ema21_rising": true,
"ema50_rising": true,
"adx_over_30": false,
"higher_highs_lows": true,
"lower_highs_lows": false,
"near_21ema": true
},
"dist_21ema_pct": 3.8,
"_no_bars": false,
"macd": {
"macd": 0.852,
"signal": 0.813,
"histogram": 0.039
},
"bollinger": {
"mid": 34.27,
"upper": 36.29,
"lower": 32.25,
"width_pct": 11.78
},
"crossover": {
"fresh_cross": null,
"pre_compressed": null,
"held_above_21": null,
"candles_since": null,
"intraday_support": false
},
"momentum": {
"roc10": 3.6,
"ret_3d": 0.93,
"ret_5d": 2.59,
"roc10_accel": -1.54,
"checks": {
"roc_over_5": false,
"rsi_in_band": true,
"macd_expanding": true,
"top_quartile_3d": false,
"no_big_down": true,
"near_high": true
},
"volume": {
"rvol": 0.08,
"checks": {
"rvol_over_2": false,
"up_vol_beats_down": true,
"obv_new_high": true,
"surge_day": false,
"pullback_declining_vol": false,
"last_up_beats_down": false
}
}
},
"relative_strength": {
"sector": "Healthcare",
"sector_etf": "XLV",
"sector_etf_ret10d": 0.86,
"checks": {
"beats_spy_all": true,
"beats_sector_10d": true,
"rs_line_at_high": true,
"sector_top3": true
}
},
"commodity": {},
"universe": {
"checks": {
"price_over_20": true,
"mcap_2b_to_200b": true,
"dollar_vol_over_10m": true,
"common_stock": true,
"no_earnings_7d": true
},
"avg_dollar_vol": 75392626.3488
},
"options": {
"checks": {
"call_vol_2x": false,
"ivr_under_40": false,
"oi_calls_above_price": true
},
"vals": {
"call_vol_mult": 0.0,
"iv_rank": 81.0
}
}
}
}
Data:
{
"prior_day": {
"high": 35.79,
"low": 35.48,
"close": 35.56,
"date": "2026-09-30"
},
"woodie_pivots": {
"PP": 35.6,
"R1": 35.71,
"S1": 35.4,
"R2": 35.91,
"S2": 35.29
},
"swing": {
"high_20d": 35.79,
"low_20d": 32.21,
"high_60d": 35.79,
"low_60d": 27.86
},
"orb": {
"high": 35.79,
"low": 35.48,
"date": "2026-09-30"
},
"vwap": 35.62,
"volume_profile": {
"poc": 34.81,
"vah": 35.63,
"val": 34.1,
"sessions": 20
},
"intraday": {
"h1_trend": "up",
"h1_last": 35.61,
"h1_ema9": 35.41,
"h1_ema21": 35.27,
"m15_trend": "up",
"m15_last": 35.61,
"m15_ema9": 35.54,
"m15_ema21": 35.47,
"rvol_intraday": 0.64,
"as_of_et": "2026-09-30 09:35"
},
"premarket": {
"date": "2026-09-30",
"high": 35.73,
"low": 35.42,
"last": 35.72,
"volume": 12993,
"gap_pct": 0.42,
"path": "04:25 35.54 -> 05:45 35.45 -> 08:05 35.58 -> 08:50 35.68 -> 09:25 35.72",
"bars": 21,
"last_bar_et": "09:25"
},
"recent_daily": [
{
"d": "2026-08-26",
"o": 33.78,
"h": 33.9,
"l": 33.36,
"c": 33.75,
"v": 3086697.285824
},
{
"d": "2026-08-27",
"o": 33.91,
"h": 34.165,
"l": 33.67,
"c": 34.1,
"v": 1866282.373548
},
{
"d": "2026-08-28",
"o": 33.78,
"h": 33.9295,
"l": 33.115,
"c": 33.23,
"v": 1518714.462588
},
{
"d": "2026-08-31",
"o": 32.76,
"h": 33.26,
"l": 32.5401,
"c": 33.16,
"v": 1733460.470967
},
{
"d": "2026-09-01",
"o": 33.33,
"h": 33.67,
"l": 33.15,
"c": 33.29,
"v": 1563240.125811
},
{
"d": "2026-09-02",
"o": 34.04,
"h": 34.5,
"l": 33.74,
"c": 34.215,
"v": 2079450.979938
},
{
"d": "2026-09-03",
"o": 34.63,
"h": 34.66,
"l": 34.08,
"c": 34.41,
"v": 890948.498911
},
{
"d": "2026-09-04",
"o": 33.96,
"h": 34.19,
"l": 33.545,
"c": 33.6,
"v": 1002605.58156
},
{
"d": "2026-09-08",
"o": 33.71,
"h": 33.84,
"l": 33.36,
"c": 33.53,
"v": 1550685.289557
},
{
"d": "2026-09-09",
"o": 33.47,
"h": 33.75,
"l": 32.98,
"c": 33.04,
"v": 2125948.441402
},
{
"d": "2026-09-10",
"o": 32.46,
"h": 32.68,
"l": 32.21,
"c": 32.23,
"v": 1015762.637089
},
{
"d": "2026-09-11",
"o": 32.45,
"h": 32.7,
"l": 32.27,
"c": 32.47,
"v": 1394020.706639
},
{
"d": "2026-09-14",
"o": 32.79,
"h": 32.96,
"l": 32.52,
"c": 32.65,
"v": 1411695.159918
},
{
"d": "2026-09-15",
"o": 32.34,
"h": 34.185,
"l": 32.34,
"c": 34.15,
"v": 3085287.288684
},
{
"d": "2026-09-16",
"o": 34.36,
"h": 34.63,
"l": 34.05,
"c": 34.4,
"v": 2885965.311903
},
{
"d": "2026-09-17",
"o": 34.28,
"h": 34.77,
"l": 34.22,
"c": 34.535,
"v": 2703043.774782
},
{
"d": "2026-09-18",
"o": 34.92,
"h": 35.15,
"l": 34.715,
"c": 34.74,
"v": 2711562.973822
},
{
"d": "2026-09-21",
"o": 34.7,
"h": 34.865,
"l": 34.36,
"c": 34.69,
"v": 1577461.899914
},
{
"d": "2026-09-22",
"o": 34.46,
"h": 35.295,
"l": 34.37,
"c": 35.22,
"v": 2297611.624967
},
{
"d": "2026-09-23",
"o": 35.39,
"h": 35.66,
"l": 34.605,
"c": 34.75,
"v": 2509746.735053
},
{
"d": "2026-09-24",
"o": 34.69,
"h": 35.03,
"l": 34.36,
"c": 34.83,
"v": 2514937.357143
},
{
"d": "2026-09-25",
"o": 34.95,
"h": 35.47,
"l": 34.7,
"c": 35.32,
"v": 3583206.004021
},
{
"d": "2026-09-28",
"o": 34.76,
"h": 35.7,
"l": 34.63,
"c": 35.36,
"v": 2794571.032575
},
{
"d": "2026-09-29",
"o": 34.94,
"h": 35.64,
"l": 34.89,
"c": 35.57,
"v": 3827544.07047
},
{
"d": "2026-09-30",
"o": 35.72,
"h": 35.79,
"l": 35.48,
"c": 35.56,
"v": 137623.087396
}
]
}
Data:
{
"sector": "Healthcare",
"etf": "XLV",
"etf_trend": "up",
"etf_r5d": 0.49,
"etf_rvol": 1.17,
"rs_5d": 0.5,
"leading": true
}
Data:
{
"estimates": [
{
"symbol": "GMAB",
"date": "2030-12-31",
"revenueLow": 6257427952,
"revenueHigh": 7163346381,
"revenueAvg": 6701900000,
"ebitdaLow": 2046239861,
"ebitdaHigh": 2407276249,
"ebitdaAvg": 2223376647,
"ebitLow": 1946781247,
"ebitHigh": 2307817635,
"ebitAvg": 2123918033,
"netIncomeLow": 1489772551,
"netIncomeHigh": 1776260763,
"netIncomeAvg": 1630333455,
"sgaExpenseLow": 1094981519,
"sgaExpenseHigh": 1253507346,
"sgaExpenseAvg": 1172759271,
"epsAvg": 2.60056,
"epsHigh": 2.83333,
"epsLow": 2.37635,
"numAnalystsRevenue": 8,
"numAnalystsEps": 11
},
{
"symbol": "GMAB",
"date": "2029-12-31",
"revenueLow": 6061777800,
"revenueHigh": 6939371000,
"revenueAvg": 6492352601,
"ebitdaLow": 2003103447,
"ebitdaHigh": 2357076802,
"ebitdaAvg": 2176771920,
"ebitLow": 1910028188,
"ebitHigh": 2264001543,
"ebitAvg": 2083696661,
"netIncomeLow": 1460608405,
"netIncomeHigh": 1741491985,
"netIncomeAvg": 1598417146,
"sgaExpenseLow": 1060744880,
"sgaExpenseHigh": 1214314101,
"sgaExpenseAvg": 1136090766,
"epsAvg": 2.54965,
"epsHigh": 2.77787,
"epsLow": 2.32983,
"numAnalystsRevenue": 13,
"numAnalystsEps": 7
},
{
"symbol": "GMAB",
"date": "2028-12-31",
"revenueLow": 5317804539,
"revenueHigh": 7152250019,
"revenueAvg": 6282504269,
"ebitdaLow": 1459563509,
"ebitdaHigh": 2898447336,
"ebitdaAvg": 2316927142,
"ebitLow": 1373490415,
"ebitHigh": 2812374242,
"ebitAvg": 2230854048,
"netIncomeLow": 1034857007,
"netIncomeHigh": 2176634589,
"netIncomeAvg": 1715188912,
"sgaExpenseLow": 930557689,
"sgaExpenseHigh": 1251565604,
"sgaExpenseAvg": 1099369601,
"epsAvg": 2.61762,
"epsHigh": 3.47197,
"epsLow": 1.65071,
"numAnalystsRevenue": 17,
"numAnalystsEps": 14
},
{
"symbol": "GMAB",
"date": "2027-12-31",
"revenueLow": 4809658458,
"revenueHigh": 5654870405,
"revenueAvg": 5222202385,
"ebitdaLow": 1132815029,
"ebitdaHigh": 1893299965,
"ebitdaAvg": 1527363864,
"ebitLow": 1054516212,
"ebitHigh": 1815001148,
"ebitAvg": 1449065047,
"netIncomeLow": 781745819,
"netIncomeHigh": 1385202912,
"netIncomeAvg": 1094826699,
"sgaExpenseLow": 841637677,
"sgaExpenseHigh": 989540532,
"sgaExpenseAvg": 913828356,
"epsAvg": 1.72826,
"epsHigh": 2.20955,
"epsLow": 1.24697,
"numAnalystsRevenue": 15,
"numAnalystsEps": 7
}
],
"price_target": {
"symbol": "GMAB",
"targetHigh": 43,
"targetLow": 38,
"targetConsensus": 40.33,
"targetMedian": 40
},
"ratings": {
"symbol": "GMAB",
"rating": "B",
"overallScore": 3,
"discountedCashFlowScore": 3,
"returnOnEquityScore": 4,
"returnOnAssetsScore": 4,
"debtToEquityScore": 1,
"priceToEarningsScore": 2,
"priceToBookScore": 2
},
"grades": [
{
"symbol": "GMAB",
"date": "2026-09-14",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2026-08-07",
"gradingCompany": "Guggenheim",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2026-07-22",
"gradingCompany": "TD Cowen",
"previousGrade": "Hold",
"newGrade": "Buy",
"action": "upgrade"
},
{
"symbol": "GMAB",
"date": "2026-07-02",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2026-06-23",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2026-04-30",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2026-02-23",
"gradingCompany": "Guggenheim",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2026-02-18",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2026-01-28",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2026-01-20",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2025-11-10",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2025-11-07",
"gradingCompany": "Truist Securities",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2025-10-15",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
},
{
"symbol": "GMAB",
"date": "2025-10-02",
"gradingCompany": "HC Wainwright & Co.",
"previousGrade": "Buy",
"newGrade": "Buy",
"action": "maintain"
}
]
}
Data:
[
{
"title": "Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4",
"url": "https://www.marketbeat.com/instant-alerts/event-genmab-eyes-three-pivotal-phase-iii-cancer-readouts-in-q4-2026-09-26/",
"source": "MarketBeat",
"date": "2026-09-26 20:03:28",
"summary": "Genmab A/S NASDAQ: GMAB expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, according to Andrew Carlsen, the company's vice president and head of investor relati",
"image": "https://images.financialmodelingprep.com/news/genmab-eyes-three-pivotal-phase-iii-cancer-readouts-in-20260926.jpg"
},
{
"title": "Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High \u2013 What\u2019s Next?",
"url": "https://www.defenseworld.net/2026/09/25/genmab-a-s-nasdaqgmab-hits-new-1-year-high-whats-next.html",
"source": "Defense World",
"date": "2026-09-25 04:53:11",
"summary": "Genmab A/S Sponsored ADR (NASDAQ: GMAB - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $35.66 and last traded at $35.3850, with a volume of 234834 shares. The stock had previously closed at $35.22. Wall Street Analysts Fo",
"image": "https://images.financialmodelingprep.com/news/genmab-as-nasdaqgmab-hits-new-1year-high-whats-next-20260925.png"
},
{
"title": "Grant of Restricted Stock Units and Warrants to Employees in Genmab",
"url": "https://www.globenewswire.com/news-release/2026/09/24/3368684/0/en/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab.html",
"source": "GlobeNewswire Inc.",
"date": "2026-09-24T18:32:00Z",
"summary": "Genmab A/S announced the grant of 13,794 restricted stock units and 13,331 warrants to employees. The RSUs have a fair value of DKK 2,268 per unit and will vest after three years, while warrants have an exercise price of DKK 2,268 with a Black-Scholes fair value of DKK 781.96, ve",
"image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce"
},
{
"title": "Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript",
"url": "https://seekingalpha.com/article/4948641-genmab-a-s-gmab-presents-at-bank-of-america-global-healthcare-conference-2026-transcript",
"source": "Seeking Alpha",
"date": "2026-09-22 10:49:47",
"summary": "Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript",
"image": "https://images.financialmodelingprep.com/news/genmab-as-gmab-presents-at-bank-of-america-global-20260922.jpg"
},
{
"title": "Genmab A/S (GMAB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript",
"url": "https://seekingalpha.com/article/4946489-genmab-a-s-gmab-presents-at-morgan-stanley-24th-annual-global-healthcare-conference",
"source": "Seeking Alpha",
"date": "2026-09-15 17:01:48",
"summary": "Genmab A/S (GMAB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript",
"image": "https://images.financialmodelingprep.com/news/genmab-as-gmab-presents-at-morgan-stanley-24th-annual-20260915.jpg"
},
{
"title": "Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 \u2013 SNS Insider",
"url": "https://www.globenewswire.com/news-release/2026/09/09/3358267/0/en/monoclonal-antibodies-market-to-grow-at-11-01-cagr-reaching-usd-791-28-billion-by-2035-sns-insider.html",
"source": "GlobeNewswire Inc.",
"date": "2026-09-09T00:30:00Z",
"summary": "The global monoclonal antibodies market is projected to grow from USD 280.15 billion in 2025 to USD 791.28 billion by 2035, driven by increasing demand for targeted therapies in oncology, autoimmune disorders, and chronic diseases. North America leads with 41% market share, while",
"image": "https://ml.globenewswire.com/Resource/Download/d6272c2e-d204-41b8-b545-a6e2e24f85c2"
},
{
"title": "Capital Increase in Genmab as a Result of Employee Warrant Exercise",
"url": "https://www.globenewswire.com/news-release/2026/09/08/3358063/0/en/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise.html",
"source": "GlobeNewswire Inc.",
"date": "2026-09-08T18:44:00Z",
"summary": "Genmab A/S announced a capital increase of 28,011 shares resulting from employee warrant exercises, raising approximately DKK 44.3 million. The new shares represent 0.04% of the company's share capital and will be listed on Nasdaq Copenhagen. The total nominal share capital after",
"image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce"
},
{
"title": "Notice to Convene an Extraordinary General Meeting of Genmab A/S",
"url": "https://www.globenewswire.com/news-release/2026/09/08/3357422/0/en/notice-to-convene-an-extraordinary-general-meeting-of-genmab-a-s.html",
"source": "GlobeNewsWire",
"date": "2026-09-08 06:00:00",
"summary": "Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 \u2013 Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be held on Wednesday, October 7, 2026, at 3:00 PM CEST at Genmab'",
"image": "https://images.financialmodelingprep.com/news/notice-to-convene-an-extraordinary-general-meeting-of-genmab-20260908.jpg"
},
{
"title": "Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight",
"url": "https://www.globenewswire.com/news-release/2026/09/03/3356185/0/en/advanced-endometrial-cancer-clinical-trial-pipeline-analysis-25-key-companies-shaping-the-future-of-advanced-endometrial-cancer-therapeutics-space-delveinsight.html",
"source": "GlobeNewswire Inc.",
"date": "2026-09-03T17:00:00Z",
"summary": "DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antib",
"image": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db"
},
{
"title": "Genmab to Participate in Upcoming Investor Conferences",
"url": "https://www.globenewswire.com/news-release/2026/08/25/3350489/0/en/genmab-to-participate-in-upcoming-investor-conferences.html",
"source": "GlobeNewswire Inc.",
"date": "2026-08-25T13:00:00Z",
"summary": "Genmab A/S announced that members of its Executive Committee will participate in fireside chats at three major healthcare investor conferences in September 2026: Wells Fargo Healthcare Conference (September 9), Morgan Stanley Global Healthcare Conference (September 15), and Bank ",
"image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce"
},
{
"title": "Here Are Wednesday\u2019s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More",
"url": "https://247wallst.com/investing/2026/08/12/here-are-wednesdays-top-wall-street-analyst-research-calls-the-gap-genmab-hilton-worldwide-intuitive-surgical-mariott-international-merck-novo-nordisk-okta-and-more/",
"source": "247 Wallst",
"date": "2026-08-12 07:53:41",
"summary": "With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even opens.",
"image": "https://images.financialmodelingprep.com/news/here-are-wednesdays-top-wall-street-analyst-research-calls-20260812.jpg"
},
{
"title": "Genmab A/S (GMAB) Q2 2026 Earnings Call Transcript",
"url": "https://seekingalpha.com/article/4933005-genmab-a-s-gmab-q2-2026-earnings-call-transcript",
"source": "Seeking Alpha",
"date": "2026-08-07 08:14:24",
"summary": "Genmab A/S (GMAB) Q2 2026 Earnings Call Transcript",
"image": "https://images.financialmodelingprep.com/news/genmab-as-gmab-q2-2026-earnings-call-transcript-20260807.jpg"
},
{
"title": "Genmab A/S Q2 Earnings Call Highlights",
"url": "https://www.marketbeat.com/instant-alerts/genmab-as-q2-earnings-call-highlights-2026-08-06/",
"source": "MarketBeat",
"date": "2026-08-06 14:04:58",
"summary": "Genmab A/S NASDAQ: GMAB reported first-half 2026 revenue growth of 25% year over year and raised its full-year financial outlook, citing continued momentum from DARZALEX, EPKINLY and the broader portfolio. The company also outlined upcoming late-stage trial readouts and announced",
"image": "https://images.financialmodelingprep.com/news/genmab-as-q2-earnings-call-highlights-20260806.jpg"
},
{
"title": "Avidity Partners Management LP Cuts Stock Holdings in Genmab A/S Sponsored ADR $GMAB",
"url": "https://www.defenseworld.net/2026/08/01/avidity-partners-management-lp-cuts-stock-holdings-in-genmab-a-s-sponsored-adr-gmab.html",
"source": "Defense World",
"date": "2026-08-01 03:49:51",
"summary": "Avidity Partners Management LP reduced its stake in Genmab A/S Sponsored ADR (NASDAQ: GMAB) by 45.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,000 shar",
"image": "https://images.financialmodelingprep.com/news/avidity-partners-management-lp-cuts-stock-holdings-in-genmab-as-20260801.png"
},
{
"title": "Genmab's H1 Preview: Darzalex Beats The Sales Outlook",
"url": "https://seekingalpha.com/article/4926101-genmabs-h1-preview-darzalex-beats-the-sales-outlook",
"source": "Seeking Alpha",
"date": "2026-07-28 02:38:06",
"summary": "Genmab's buy rating with a $36 12-month target implies roughly 25% upside from the $28.74 reference price. DARZALEX H1 sales reached $8.17B, already exceeding half of Genmab's $16.0B full-year assumption. Holding Q2 sales flat through H2 would produce $16.59B, above the $16.4B hi",
"image": "https://images.financialmodelingprep.com/news/genmabs-h1-preview-darzalex-beats-the-sales-outlook-20260728.jpg"
},
{
"title": "Genmab and AbbVie Provide Clarification on Phase 3 EPCORE\u00ae DLBCL-1 Trial Evaluating Epcoritamab (DuoBody\u00ae-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",
"url": "https://www.globenewswire.com/news-release/2026/07/23/3332539/0/en/Genmab-and-AbbVie-Provide-Clarification-on-Phase-3-EPCORE-DLBCL-1-Trial-Evaluating-Epcoritamab-DuoBody-CD3xCD20-in-Patients-with-Relapsed-Refractory-Diffuse-Large-B-cell-Lymphoma-D.html",
"source": "GlobeNewswire Inc.",
"date": "2026-07-23T20:00:00Z",
"summary": "Genmab and AbbVie announced that the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab (a T-cell engaging bispecific antibody) failed to meet its primary endpoint of overall survival in the United States when compared to standard chemotherapy in patients with relapsed/refractor",
"image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce"
},
{
"title": "PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight",
"url": "https://www.globenewswire.com/news-release/2026/07/21/3330815/0/en/PD-1-and-PD-L1-Inhibitors-Clinical-Trial-Pipeline-Analysis-Demonstrates-180-Key-Companies-on-the-Horizon-Expected-to-Transform-the-Oncology-Space-DelveInsight.html",
"source": "GlobeNewswire Inc.",
"date": "2026-07-21T17:00:00Z",
"summary": "A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late",
"image": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db"
},
{
"title": "Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026\u20132036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight",
"url": "https://www.globenewswire.com/news-release/2026/07/21/3330817/0/en/Correction-Head-and-Neck-Squamous-Cell-Carcinoma-Market-is-Projected-to-Boost-at-a-CAGR-of-10-5-During-the-Forecast-Period-2026-2036-Due-to-the-Launch-of-Emerging-Novel-Immunothera.html",
"source": "GlobeNewswire Inc.",
"date": "2026-07-21T17:00:00Z",
"summary": "The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 acr",
"image": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db"
},
{
"title": "Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026\u20132036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight",
"url": "https://www.globenewswire.com/news-release/2026/07/13/3326387/0/en/Head-and-Neck-Squamous-Cell-Carcinoma-Market-is-Projected-to-Boost-at-a-CAGR-of-10-5-During-the-Forecast-Period-2026-2036-Due-to-the-Launch-of-Emerging-Novel-Immunotherapies-DelveI.html",
"source": "GlobeNewswire Inc.",
"date": "2026-07-13T17:00:00Z",
"summary": "The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 ",
"image": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db"
},
{
"title": "Genmab Announces TEPKINLY\u00ae (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma",
"url": "https://www.globenewswire.com/news-release/2026/07/06/3322680/0/en/Genmab-Announces-TEPKINLY-epcoritamab-in-Combination-with-Lenalidomide-and-Rituximab-is-Approved-by-the-European-Commission-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-L.html",
"source": "GlobeNewswire Inc.",
"date": "2026-07-06T17:59:00Z",
"summary": "The European Commission has approved TEPKINLY\u00ae (epcoritamab) in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma. The Phase 3 EPCORE\u00ae FL-1 trial demonstrated that the fixed-duration combination therapy reduced disease progression",
"image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce"
},
{
"title": "Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",
"url": "https://www.globenewswire.com/news-release/2026/06/13/3311409/0/en/Genmab-Announces-Epcoritamab-Monotherapy-and-Epcoritamab-Based-Combination-Regimens-Demonstrate-High-Response-Rates-in-Elderly-Patients-with-Newly-Diagnosed-Diffuse-Large-B-Cell-Ly.html",
"source": "GlobeNewswire Inc.",
"date": "2026-06-13T16:45:00Z",
"summary": "Genmab announced positive Phase 2 and Phase 1b/2 trial results for epcoritamab in elderly DLBCL patients. The monotherapy arm (EPCORE DLBCL-3) showed 67% overall response rate and 58% complete response rate, while the combination with R-mini-CHOP (EPCORE NHL-2) demonstrated 93% o",
"image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce"
},
{
"title": "Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons",
"url": "https://www.globenewswire.com/news-release/2026/05/29/3303823/0/en/Transactions-with-Shares-and-Linked-Securities-in-Genmab-A-S-Made-by-Managerial-Employees-and-Their-Closely-Associated-Persons.html",
"source": "GlobeNewswire Inc.",
"date": "2026-05-29T20:35:00Z",
"summary": "Genmab A/S announced the disclosure of share transactions made by managerial employees and their closely associated persons in accordance with EU market abuse regulations. The company also announced a capital increase of 2,346 shares resulting from employee warrant exercises.",
"image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce"
},
{
"title": "Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - Clinical Trials, Regulatory Approvals, Development Platforms",
"url": "https://www.globenewswire.com/news-release/2026/04/21/3277650/28124/en/Bispecific-Antibody-Drug-Conjugates-Market-Landscape-Report-2026-A-2-Billion-Opportunity-by-2030-with-the-1st-Approved-BsADC-by-2028-Clinical-Trials-Regulatory-Approvals-Developmen.html",
"source": "GlobeNewswire Inc.",
"date": "2026-04-21T08:49:00Z",
"summary": "The bispecific antibody drug conjugate (BsADC) market is expected to reach over $2 billion by 2030, with the first BsADC approval anticipated by 2028. Over 150 clinical trials are underway globally, with China leading development efforts. Key candidates like Izalontamab brengitec",
"image": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7"
},
{
"title": "Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook",
"url": "https://www.globenewswire.com/news-release/2026/04/21/3277647/28124/en/Bispecific-Antibody-Market-Landscape-Report-2026-A-Potential-60-Opportunity-by-2031-Insight-on-More-than-550-Clinical-Trials-Antibody-Dosage-Patent-Price-Sales-Outlook.html",
"source": "GlobeNewswire Inc.",
"date": "2026-04-21T08:34:00Z",
"summary": "The bispecific antibodies market is projected to reach over $60 billion by 2031, growing from $16 billion in 2025. With 18 approved bispecific antibodies and over 550 clinical trials underway, the market is transitioning toward commercial maturity driven by clinical progress in c",
"image": "https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7"
},
{
"title": "Genmab A/S Share Capital Reduction",
"url": "https://www.globenewswire.com/news-release/2026/04/17/3276312/0/en/Genmab-A-S-Share-Capital-Reduction.html",
"source": "GlobeNewswire Inc.",
"date": "2026-04-17T14:56:00Z",
"summary": "Genmab A/S has completed a share capital reduction by canceling 1.9 million treasury shares, reducing total share capital from DKK 64.25 million to DKK 62.35 million. The reduction was approved at the Annual General Meeting on March 19, 2026, and registered with Danish authoritie",
"image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce"
}
]
Data:
[
{
"symbol": "GMAB",
"date": "2026-11-05",
"epsActual": null,
"epsEstimated": 0.37,
"revenueActual": null,
"revenueEstimated": 1213042000,
"lastUpdated": "2026-09-30"
},
{
"symbol": "GMAB",
"date": "2026-08-06",
"epsActual": 0.54,
"epsEstimated": 0.37,
"revenueActual": 1155000000,
"revenueEstimated": 1116420000,
"lastUpdated": "2026-09-30"
},
{
"symbol": "GMAB",
"date": "2026-05-07",
"epsActual": 0.087,
"epsEstimated": 0.15,
"revenueActual": 896000000,
"revenueEstimated": 905773700,
"lastUpdated": "2026-08-07"
},
{
"symbol": "GMAB",
"date": "2026-02-17",
"epsActual": 0.05,
"epsEstimated": 0.46,
"revenueActual": 1058000000,
"revenueEstimated": 1066136000,
"lastUpdated": "2026-05-17"
},
{
"symbol": "GMAB",
"date": "2025-11-06",
"epsActual": 0.65,
"epsEstimated": 0.48,
"revenueActual": 1022000000,
"revenueEstimated": 1011055920,
"lastUpdated": "2026-02-06"
}
]
Data:
{
"borrow": [],
"short_interest": [
{
"symbol": "GMAB",
"file_date": "",
"error": "Symbol not found in FINRA biweekly file",
"days_to_cover": null
}
],
"ftd": {
"symbol": "GMAB",
"periods": [
{
"file_period": "202606b",
"settlement_date": "20260630",
"quantity_fails": 85,
"price": 26.02
},
{
"file_period": "202607a",
"settlement_date": "20260709",
"quantity_fails": 1,
"price": 29.54
},
{
"file_period": "202607b",
"settlement_date": "20260729",
"quantity_fails": 70,
"price": 29.0
},
{
"file_period": "202608a",
"settlement_date": "20260814",
"quantity_fails": 378,
"price": 31.34
},
{
"file_period": "202608b",
"settlement_date": "20260828",
"quantity_fails": 197,
"price": 34.1
},
{
"file_period": "202609a",
"settlement_date": "20260909",
"quantity_fails": 4958,
"price": 33.53
}
],
"trend": "rising",
"trend_description": "FTD quantity increasing \u2014 settlement pressure building, potential squeeze precursor"
}
}
Data:
{
"insider": {
"status": "not_found",
"endpoint": "search-insider-trades",
"provided": "symbol=\"GMAB\"",
"message": "No data returned for search-insider-trades with symbol=\"GMAB\". The identifier may not exist, or may have no data for this endpoint. Use the 'search' tool to verify the symbol/cik/name."
},
"congress": [
{
"symbol": "GMAB",
"senateID": "C000174",
"disclosureDate": "2021-05-17",
"transactionDate": "2020-11-20",
"firstName": "Thomas Richard",
"lastName": "Carper",
"office": "Thomas R. Carper",
"district": "DE",
"owner": "Spouse",
"assetDescription": "Genmab A/S",
"assetType": "Stock",
"type": "Purchase",
"amount": "$1,001 - $15,000",
"capitalGainsOver200USD": "False",
"comment": "--",
"link": "https://efdsearch.senate.gov/search/view/ptr/6697156a-918e-4db5-86f3-bf7abe42c239/"
},
{
"symbol": "GMAB",
"senateID": "C000174",
"disclosureDate": "2020-12-02",
"transactionDate": "2020-11-20",
"firstName": "Thomas Richard",
"lastName": "Carper",
"office": "Thomas R Carper",
"district": "DE",
"owner": "Spouse",
"assetDescription": "Genmab A/S",
"assetType": "Stock",
"type": "Purchase",
"amount": "$1,001 - $15,000",
"capitalGainsOver200USD": "False",
"comment": "",
"link": "https://efdsearch.senate.gov/search/view/ptr/35aec3a8-60a7-4f06-bae3-3b202949e5e5/"
},
{
"symbol": "GMAB",
"senateID": "G000583",
"disclosureDate": "2025-02-11",
"transactionDate": "2025-01-16",
"firstName": "Josh S.",
"lastName": "Gottheimer",
"office": "Josh Gottheimer",
"district": "NJ05",
"owner": "Joint",
"assetDescription": "Genmab A/S - American Depositary Shares",
"assetType": "Stock",
"type": "Purchase",
"amount": "$1,001 - $15,000",
"capitalGainsOver200USD": "False",
"comment": "",
"link": "https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2025/20026732.pdf"
},
{
"symbol": "GMAB",
"senateID": "G000583",
"disclosureDate": "2025-01-14",
"transactionDate": "2024-12-16",
"firstName": "Josh S.",
"lastName": "Gottheimer",
"office": "Josh Gottheimer",
"district": "NJ05",
"owner": "Joint",
"assetDescription": "Genmab A/S - American Depositary Shares",
"assetType": "Stock",
"type": "Sale (Full)",
"amount": "$1,001 - $15,000",
"capitalGainsOver200USD": "False",
"comment": "",
"link": "https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2025/20026533.pdf"
},
{
"symbol": "GMAB",
"senateID": "G000583",
"disclosureDate": "2024-08-15",
"transactionDate": "2024-07-19",
"firstName": "Josh S.",
"lastName": "Gottheimer",
"office": "Josh Gottheimer",
"district": "NJ05",
"owner": "Joint",
"assetDescription": "Genmab A/S - American Depositary Shares",
"assetType": "Stock",
"type": "Purchase",
"amount": "$1,001 - $15,000",
"capitalGainsOver200USD": "False",
"comment": "",
"link": "https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2024/20025678.pdf"
},
{
"symbol": "GMAB",
"senateID": "G000583",
"disclosureDate": "2024-07-09",
"transactionDate": "2024-06-18",
"firstName": "Josh S.",
"lastName": "Gottheimer",
"office": "Josh Gottheimer",
"district": "NJ05",
"owner": "Joint",
"assetDescription": "Genmab A/S - American Depositary Shares",
"assetType": "Stock",
"type": "Sale (Full)",
"amount": "$1,001 - $15,000",
"capitalGainsOver200USD": "False",
"comment": "",
"link": "https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2024/20025419.pdf"
},
{
"symbol": "GMAB",
"senateID": "G000583",
"disclosureDate": "2023-11-11",
"transactionDate": "2023-10-16",
"firstName": "Josh S.",
"lastName": "Gottheimer",
"office": "Josh Gottheimer",
"district": "NJ05",
"owner": "Joint",
"assetDescription": "Genmab A/S - American Depositary Shares",
"assetType": "Stock",
"type": "Purchase",
"amount": "$1,001 - $15,000",
"capitalGainsOver200USD": "False",
"comment": "",
"link": "https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2023/20023973.pdf"
},
{
"symbol": "GMAB",
"senateID": "G000583",
"disclosureDate": "2023-10-15",
"transactionDate": "2023-09-15",
"firstName": "Josh S.",
"lastName": "Gottheimer",
"office": "Josh Gottheimer",
"district": "NJ05",
"owner": "Joint",
"assetDescription": "Genmab A/S - American Depositary Shares",
"assetType": "Stock",
"type": "Sale (Full)",
"amount": "$1,001 - $15,000",
"capitalGainsOver200USD": "False",
"comment": "",
"link": "https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2023/20023833.pdf"
},
{
"symbol": "GMAB",
"senateID": "G000583",
"disclosureDate": "2023-08-21",
"transactionDate": "2023-07-19",
"firstName": "Josh S.",
"lastName": "Gottheimer",
"office": "Josh Gottheimer",
"district": "NJ05",
"owner": "Joint",
"assetDescription": "Genmab A/S - American Depositary Shares",
"assetType": "Stock",
"type": "Purchase",
"amount": "$1,001 - $15,000",
"capitalGainsOver200USD": "False",
"comment": "",
"link": "https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2023/20023500.pdf"
},
{
"symbol": "GMAB",
"senateID": "G000583",
"disclosureDate": "2023-08-21",
"transactionDate": "2023-07-20",
"firstName": "Josh S.",
"lastName": "Gottheimer",
"office": "Josh Gottheimer",
"district": "NJ05",
"owner": "Joint",
"assetDescription": "Genmab A/S - American Depositary Shares",
"assetType": "Stock",
"type": "Purchase",
"amount": "$1,001 - $15,000",
"capitalGainsOver200USD": "False",
"comment": "",
"link": "https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2023/20023500.pdf"
},
{
"symbol": "GMAB",
"senateID": "G000599",
"disclosureDate": "2023-08-13",
"transactionDate": "2023-07-10",
"firstName": "Daniel",
"lastName": "Goldman",
"office": "Daniel Goldman",
"district": "NY10",
"owner": "",
"assetDescription": "Genmab A/S - American Depositary Shares",
"assetType": "Stock",
"type": "Sale (Full)",
"amount": "$50,001 - $100,000",
"capitalGainsOver200USD": "False",
"comment": "",
"link": "https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2023/20023404.pdf"
},
{
"symbol": "GMAB",
"senateID": "G000599",
"disclosureDate": "2023-04-17",
"transactionDate": "2023-03-31",
"firstName": "Daniel",
"lastName": "Goldman",
"office": "Daniel Goldman",
"district": "NY10",
"owner": "",
"assetDescription": "Genmab A/S - American Depositary Shares",
"assetType": "Stock",
"type": "Sale (Partial)",
"amount": "$1,001 - $15,000",
"capitalGainsOver200USD": "False",
"comment": "",
"link": "https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2023/20022653.pdf"
}
],
"dark_pool": [
{
"ticker": "GMAB",
"executed_at": "2026-09-30T13:37:24.666000Z",
"size": 1800.0,
"price": 35.6,
"premium": 64080.0,
"volume": 1800.0,
"trade_code": " "
},
{
"ticker": "GMAB",
"executed_at": "2026-09-30T13:37:33.305000Z",
"size": 1600.0,
"price": 35.62,
"premium": 56991.99999999999,
"volume": 1600.0,
"trade_code": " "
},
{
"ticker": "GMAB",
"executed_at": "2026-09-30T13:37:33.329000Z",
"size": 1200.0,
"price": 35.65,
"premium": 42780.0,
"volume": 1200.0,
"trade_code": " "
},
{
"ticker": "GMAB",
"executed_at": "2026-09-30T13:37:25.065000Z",
"size": 800.0,
"price": 35.61,
"premium": 28488.0,
"volume": 800.0,
"trade_code": "F"
},
{
"ticker": "GMAB",
"executed_at": "2026-09-30T13:37:33.328000Z",
"size": 500.0,
"price": 35.65,
"premium": 17825.0,
"volume": 500.0,
"trade_code": " "
},
{
"ticker": "GMAB",
"executed_at": "2026-09-30T13:37:24.587000Z",
"size": 400.0,
"price": 35.58,
"premium": 14232.0,
"volume": 400.0,
"trade_code": "F"
},
{
"ticker": "GMAB",
"executed_at": "2026-09-30T13:37:33.366000Z",
"size": 300.0,
"price": 35.665,
"premium": 10699.5,
"volume": 300.0,
"trade_code": " "
},
{
"ticker": "GMAB",
"executed_at": "2026-09-30T13:37:33.400000Z",
"size": 284.0,
"price": 35.65,
"premium": 10124.6,
"volume": 284.0,
"trade_code": " "
}
],
"ats": {
"symbol": "GMAB",
"date": "20260929",
"ats_volume": 0,
"total_volume": 1796455,
"ats_ratio": 0.0,
"ats_pct": 0.0,
"signal": "Low",
"history": [
{
"date": "20260929",
"ats_ratio": 0.0
},
{
"date": "20260928",
"ats_ratio": 0.0
},
{
"date": "20260925",
"ats_ratio": 0.0
},
{
"date": "20260924",
"ats_ratio": 0.0
},
{
"date": "20260923",
"ats_ratio": 0.0
}
]
},
"polygon_dp": {
"ticker": "GMAB",
"days": [
{
"date": "2026-09-30",
"close": 35.56,
"vwap": 35.62,
"volume": 137623,
"vwap_discount_pct": 0.17
},
{
"date": "2026-09-29",
"close": 35.57,
"vwap": 35.33,
"volume": 3827544,
"vwap_discount_pct": -0.68
},
{
"date": "2026-09-28",
"close": 35.36,
"vwap": 35.21,
"volume": 2794571,
"vwap_discount_pct": -0.42
},
{
"date": "2026-09-25",
"close": 35.32,
"vwap": 35.07,
"volume": 3583206,
"vwap_discount_pct": -0.7
},
{
"date": "2026-09-24",
"close": 34.83,
"vwap": 34.72,
"volume": 2514937,
"vwap_discount_pct": -0.3
}
],
"avg_vwap_discount_pct": -0.39,
"signal": "Distribution"
},
"options_flow": [],
"net_premium": {
"ticker": "GMAB",
"net_call_premium": "565.00",
"net_put_premium": "150.00",
"call_premium": "565.00",
"put_premium": "150.00",
"bullish_premium": "565.00",
"bearish_premium": "150.00",
"put_call_ratio": "0.3333333333333333333333333333",
"iv_rank": "80.7241",
"implied_move_perc": "0.114",
"gex_ratio": null,
"gex_net_change": null,
"gex_call": "157992.3884",
"gex_put": "-40217.7605",
"gex_net": 117774.6279,
"gex_call_delta": "2605663.2318",
"gex_put_delta": "-256096.5953",
"gex_date": "2026-09-30"
},
"hot_chains": [
{
"underlying_symbol": "GMAB",
"expires": "2026-12-18",
"open_interest": 3399,
"option_type": "call",
"delta": 0.365247627409594,
"ask_volume": 1,
"last_price": "2.40",
"implied_volatility": "0.581694072050175",
"gamma": 0.0424812775259204,
"avg_price": "2.40",
"bid_volume": 0,
"nbbo_ask": "2.50",
"strike": "40",
"option_symbol": "GMAB261218C00040000",
"total_premium": "240.00",
"iv": 0.533315018944349,
"volume": 1,
"nbbo_bid": "1.75"
},
{
"underlying_symbol": "GMAB",
"expires": "2027-01-15",
"open_interest": 1551,
"option_type": "put",
"delta": -0.25023533866288,
"ask_volume": 1,
"last_price": "1.50",
"implied_volatility": "0.541126800071174",
"gamma": 0.0262962584519143,
"avg_price": "1.50",
"bid_volume": 0,
"nbbo_ask": "4.20",
"strike": "30",
"option_symbol": "GMAB270115P00030000",
"total_premium": "150.00",
"iv": 0.626360983838175,
"volume": 1,
"nbbo_bid": "0.75"
},
{
"underlying_symbol": "GMAB",
"expires": "2027-05-21",
"open_interest": 0,
"option_type": "call",
"delta": 0.2231639159677376,
"ask_volume": 1,
"last_price": "1.75",
"implied_volatility": "0.464307960003894",
"gamma": 0.0232513626778726,
"avg_price": "1.75",
"bid_volume": 0,
"nbbo_ask": "1.80",
"strike": "50",
"option_symbol": "GMAB270521C00050000",
"total_premium": "175.00",
"iv": 0.451123117553387,
"volume": 1,
"nbbo_bid": "1.05"
},
{
"underlying_symbol": "GMAB",
"expires": "2027-02-19",
"open_interest": 19,
"option_type": "call",
"delta": 0.2128371879289579,
"ask_volume": 1,
"last_price": "1.50",
"implied_volatility": "0.571263298462831",
"gamma": 0.0233351936702461,
"avg_price": "1.50",
"bid_volume": 0,
"nbbo_ask": "4.30",
"strike": "50",
"option_symbol": "GMAB270219C00050000",
"total_premium": "150.00",
"iv": 0.559988789479564,
"volume": 1,
"nbbo_bid": "0.30"
},
{
"underlying_symbol": "GMAB",
"expires": "2026-12-18",
"open_interest": 16727,
"option_type": "call",
"delta": 0.838157188591801,
"ask_volume": 0,
"last_price": null,
"implied_volatility": null,
"gamma": 0.0358421026586227,
"avg_price": null,
"bid_volume": 0,
"nbbo_ask": null,
"strike": "30",
"option_symbol": "GMAB261218C00030000",
"total_premium": "0",
"iv": 0.412148284954827,
"volume": 0,
"nbbo_bid": null
},
{
"underlying_symbol": "GMAB",
"expires": "2027-01-15",
"open_interest": 4068,
"option_type": "call",
"delta": 0.417173502919837,
"ask_volume": 0,
"last_price": null,
"implied_volatility": null,
"gamma": 0.0345872713905534,
"avg_price": null,
"bid_volume": 0,
"nbbo_ask": null,
"strike": "40",
"option_symbol": "GMAB270115C00040000",
"total_premium": "0",
"iv": 0.58462421404347,
"volume": 0,
"nbbo_bid": null
},
{
"underlying_symbol": "GMAB",
"expires": "2027-01-15",
"open_interest": 3542,
"option_type": "call",
"delta": 0.585393231008422,
"ask_volume": 0,
"last_price": null,
"implied_volatility": null,
"gamma": 0.0334129158324893,
"avg_price": null,
"bid_volume": 0,
"nbbo_ask": null,
"strike": "35",
"option_symbol": "GMAB270115C00035000",
"total_premium": "0",
"iv": 0.604326500521996,
"volume": 0,
"nbbo_bid": null
},
{
"underlying_symbol": "GMAB",
"expires": "2026-10-16",
"open_interest": 2382,
"option_type": "call",
"delta": 0.5738170596131,
"ask_volume": 0,
"last_price": null,
"implied_volatility": null,
"gamma": 0.0684786211328822,
"avg_price": null,
"bid_volume": 0,
"nbbo_ask": null,
"strike": "35",
"option_symbol": "GMAB261016C00035000",
"total_premium": "0",
"iv": 0.76187494335652,
"volume": 0,
"nbbo_bid": null
}
],
"gamma_profile": {
"ticker": "GMAB",
"spot": 35.67,
"date": "2026-09-30",
"flip_point": 25.28,
"net_gex": 117774.63,
"call_walls": [
{
"strike": 30.0,
"gex": 65414.46
},
{
"strike": 35.0,
"gex": 46286.99
},
{
"strike": 40.0,
"gex": 35831.22
}
],
"put_walls": [
{
"strike": 35.0,
"gex": -19134.13
},
{
"strike": 30.0,
"gex": -17521.51
},
{
"strike": 25.0,
"gex": -2220.53
}
],
"by_strike": [
{
"strike": 12.5,
"call_gex": 0.0,
"put_gex": -24.56,
"net_gex": -24.56
},
{
"strike": 15.0,
"call_gex": 3.12,
"put_gex": -76.17,
"net_gex": -73.05
},
{
"strike": 17.5,
"call_gex": 1.31,
"put_gex": -5.62,
"net_gex": -4.31
},
{
"strike": 20.0,
"call_gex": 10.66,
"put_gex": -473.75,
"net_gex": -463.08
},
{
"strike": 22.5,
"call_gex": 8.59,
"put_gex": -473.47,
"net_gex": -464.88
},
{
"strike": 25.0,
"call_gex": 551.89,
"put_gex": -2220.53,
"net_gex": -1668.64
},
{
"strike": 30.0,
"call_gex": 65414.46,
"put_gex": -17521.51,
"net_gex": 47892.95
},
{
"strike": 35.0,
"call_gex": 46286.99,
"put_gex": -19134.13,
"net_gex": 27152.85
},
{
"strike": 40.0,
"call_gex": 35831.22,
"put_gex": -243.54,
"net_gex": 35587.68
},
{
"strike": 45.0,
"call_gex": 9835.67,
"put_gex": -42.18,
"net_gex": 9793.49
},
{
"strike": 50.0,
"call_gex": 48.49,
"put_gex": -2.3,
"net_gex": 46.19
}
]
},
"oi_changes": {
"net_call_oi_change": 4,
"net_put_oi_change": 0,
"top": [
{
"strike": "40",
"oi_change": 5,
"type": "call"
},
{
"strike": "35",
"oi_change": -1,
"type": "call"
},
{
"strike": "30",
"oi_change": 0,
"type": "call"
},
{
"strike": "35",
"oi_change": 0,
"type": "call"
},
{
"strike": "40",
"oi_change": 0,
"type": "call"
}
]
},
"opds": {
"opds": -2.6,
"D": -9.2,
"P": 35.8,
"O": 17.4,
"C": 28.7,
"signal": "NEUTRAL",
"direction": "bearish",
"coverage": 0.7,
"ranked": true,
"components": {
"M": 25.4,
"T": 63.7,
"RS": 28.2,
"V": 26.6,
"F": 58.0,
"OI": 100.0,
"S": -100.0,
"IV": null,
"B": null,
"Liquidity": 3.4,
"OpeningConfidence": null,
"FlowAgreement": 66.7,
"StrikeBreadth": null
},
"drivers": [
"+ open-interest change +100",
"- skew -100",
"+ trend +64",
"+ aggressive flow +58",
"+ relative strength +28"
]
}
}
Data:
{
"vix": 15.67,
"sp500": 7743.41,
"fed_funds": 3.63,
"yield_curve_10y2y": 0.36,
"hy_spread": 2.8,
"treasury": {
"date": "2026-09-28",
"month1": 4.04,
"month2": 4.2,
"month3": 4.28,
"month6": 4.41,
"year1": 4.59,
"year2": 4.92,
"year3": 5.01,
"year5": 5.06,
"year7": 5.15,
"year10": 5.24,
"year20": 5.6,
"year30": 5.56
},
"events": [
{
"title": "Core PCE Price Index m/m",
"currency": "USD",
"date": "2026-09-30",
"time_utc": "12:30",
"impact": "High",
"forecast": "0.3%",
"previous": "0.2%",
"actual": null,
"minutes_until": -8
},
{
"title": "Final GDP q/q",
"currency": "USD",
"date": "2026-09-30",
"time_utc": "12:30",
"impact": "High",
"forecast": "1.5%",
"previous": "1.5%",
"actual": null,
"minutes_until": -8
},
{
"title": "Average Hourly Earnings m/m",
"currency": "USD",
"date": "2026-10-02",
"time_utc": "12:30",
"impact": "High",
"forecast": "0.3%",
"previous": "0.3%",
"actual": null,
"minutes_until": 2871
},
{
"title": "Non-Farm Employment Change",
"currency": "USD",
"date": "2026-10-02",
"time_utc": "12:30",
"impact": "High",
"forecast": "90K",
"previous": "162K",
"actual": null,
"minutes_until": 2871
},
{
"title": "Unemployment Rate",
"currency": "USD",
"date": "2026-10-02",
"time_utc": "12:30",
"impact": "High",
"forecast": "4.1%",
"previous": "4.1%",
"actual": null,
"minutes_until": 2871
}
]
}
Data:
{
"days": 103,
"patterns": [
{
"name": "VWAP Touch",
"count": 103,
"pct": 100
},
{
"name": "9 EMA Touch",
"count": 103,
"pct": 100
},
{
"name": "21 EMA Touch",
"count": 103,
"pct": 100
},
{
"name": "ORB Breakout",
"count": 102,
"pct": 99
},
{
"name": "Woodie Pivot Touch",
"count": 93,
"pct": 90
},
{
"name": "PDH/PDL Touch",
"count": 89,
"pct": 86
},
{
"name": "Open Retracement",
"count": 65,
"pct": 63
},
{
"name": "Gap Fill",
"count": 56,
"pct": 54
},
{
"name": "High Vol Open",
"count": 29,
"pct": 28
},
{
"name": "Darvas Box",
"count": 28,
"pct": 27
},
{
"name": "Power Hour",
"count": 20,
"pct": 19
}
]
}